Q1: 2026-05-07 Earnings Summary
EPS of -$0.54 beats by $0.10
| Revenue of $8.21M (-12.80% Y/Y) beats by $1.26M
Assembly Biosciences, Inc. (ASMB) Bank of America Global Healthcare Conference 2026 May 13, 2026 7:35 PM EDT
Company Participants
Anuj Gaggar – Chief Medical Officer
Presentation
Operator
Here at the bank. And with me on the stage is Assembly Biosciences and Anuj Gaggar, Chief Medical Officer. Thank you so much for joining us.
Anuj Gaggar
Chief Medical Officer
Thanks for having us.
Question-and-Answer Session
Operator
Excellent. Well, maybe to start broadly for those less familiar with the Assembly story. Can you give us a quick overview of your work in virology?
Anuj Gaggar
Chief Medical Officer
Yes. Thanks. First of all, we’re very excited to be here and share our story with everyone. Assembly is a company that’s a clinical stage company that is really focused on patients who are still suffering from serious viral illnesses. We’re a full R&D company, research and development, and we have a broad partnership with Gilead Sciences, who, as you know, is a leader in antiviral discovery and development. Over the past 2.5 years, we have brought 4 new molecules into the clinic and have generated really positive data on each of those molecules. Most recently, we’ve had 2 of those molecules, our HSV programs, optioned by Gilead Sciences on the strength of the Phase Ib data. And we’re excited for the next year where we’ll move our other programs into value inflection points as well.
Operator
Great. Maybe just to take a step back, how would you frame the unmet need in hepatitis B, hep D, HSV? Is this still a space that supports meaningful innovation despite the availability of both vaccines and antivirals?
Anuj Gaggar
Chief Medical Officer
Yes. In a word, absolutely. I think what we do at Assembly is we look for the places where there are still unmet needs for
